Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical, Inc. (ISRG) Rises As Market Takes a Dip: Key Facts
In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $426.61, indicating a +1.91% shift from the previous trading day.
Intuitive Surgical (ISRG) Upgraded to Buy: Here's Why
Intuitive Surgical (ISRG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will ISRG's Cost Leverage Aid Margins Amid Tariff & Input Inflation?
ISRG lifts margins despite tariffs, using scale, cost cuts and da Vinci 5 adoption to offset inflation as 2026 cost pressures build.
ISRG Falls 11% in a Month: Is a Reversal on the Cards for the Stock?
Intuitive Surgical falls 11% in a month despite strong revenues, procedure growth and da Vinci 5 adoption, raising questions about a potential rebound.
Can ISRG's Digital Roadmap Unlock the Next Phase of Robotic Surgery?
Intuitive Surgical is building an AI-driven surgical ecosystem, using da Vinci 5 data and connected workflows to deepen its robotic surgery moat.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here is Why Growth Investors Should Buy Intuitive Surgical (ISRG) Now
Intuitive Surgical (ISRG) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ISRG vs. MDT: Which Surgical Robot Stock Is the Better Buy?
ISRG is widening its robotic surgery lead with faster growth, rising procedures and a recurring revenue model as Medtronic builds Hugo.
ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?
ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.
Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock?
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
Intuitive Surgical's ISRG single-port (SP) platform emerges as one of its most intriguing long-term growth opportunities, though the key question remains whether it can unlock incremental total addressable market (TAM) or simply serve as a substitution within existing robotic procedures.
